These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 34359640)

  • 1. Precision Medicine and Triple-Negative Breast Cancer: Current Landscape and Future Directions.
    Hossain F; Majumder S; David J; Miele L
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type.
    Subhan MA; Parveen F; Shah H; Yalamarty SSK; Ataide JA; Torchilin VP
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190133
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Landscape of Targeted Therapies in TNBC.
    Vagia E; Mahalingam D; Cristofanilli M
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32276534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research advances and new challenges in overcoming triple-negative breast cancer.
    Zong Y; Pegram M
    Cancer Drug Resist; 2021; 4(3):517-542. PubMed ID: 34888495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advancements and challenges in triple-negative breast cancer: a comprehensive review of therapeutic and diagnostic strategies.
    Xiong N; Wu H; Yu Z
    Front Oncol; 2024; 14():1405491. PubMed ID: 38863622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular subtypes and precision treatment of triple-negative breast cancer.
    Zhao S; Zuo WJ; Shao ZM; Jiang YZ
    Ann Transl Med; 2020 Apr; 8(7):499. PubMed ID: 32395543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
    Coussy F; de Koning L; Lavigne M; Bernard V; Ouine B; Boulai A; El Botty R; Dahmani A; Montaudon E; Assayag F; Morisset L; Huguet L; Sourd L; Painsec P; Callens C; Chateau-Joubert S; Servely JL; Larcher T; Reyes C; Girard E; Pierron G; Laurent C; Vacher S; Baulande S; Melaabi S; Vincent-Salomon A; Gentien D; Dieras V; Bieche I; Marangoni E
    Int J Cancer; 2019 Oct; 145(7):1902-1912. PubMed ID: 30859564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting CSC in a Most Aggressive Subtype of Breast Cancer TNBC.
    Bao B; Prasad AS
    Adv Exp Med Biol; 2019; 1152():311-334. PubMed ID: 31456192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab.
    Bagegni NA; Davis AA; Clifton KK; Ademuyiwa FO
    Breast Cancer (Dove Med Press); 2022; 14():113-123. PubMed ID: 35515356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Triple-negative breast cancer: new treatment strategies in the era of precision medicine.
    Wu SY; Wang H; Shao ZM; Jiang YZ
    Sci China Life Sci; 2021 Mar; 64(3):372-388. PubMed ID: 32803712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in Single-Cell Sequencing Technology and Its Applications in Triple-Negative Breast Cancer.
    Li M; Yan T; Wang M; Cai Y; Wei Y
    Breast Cancer (Dove Med Press); 2022; 14():465-474. PubMed ID: 36540278
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer.
    Ensenyat-Mendez M; Llinàs-Arias P; Orozco JIJ; Íñiguez-Muñoz S; Salomon MP; Sesé B; DiNome ML; Marzese DM
    Front Oncol; 2021; 11():681476. PubMed ID: 34221999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The evolving management of metastatic triple negative breast cancer.
    Malhotra MK; Emens LA
    Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular Classification and Future Therapeutic Challenges of Triple-negative Breast Cancer.
    Garmpis N; Damaskos C; Garmpi A; Nikolettos K; Dimitroulis D; Diamantis E; Farmaki P; Patsouras A; Voutyritsa E; Syllaios A; Zografos CG; Antoniou EA; Nikolettos N; Kostakis A; Kontzoglou K; Schizas D; Nonni A
    In Vivo; 2020; 34(4):1715-1727. PubMed ID: 32606140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted Therapies for Triple-Negative Breast Cancer.
    Lyons TG
    Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Precision medicine based on tumorigenic signaling pathways for triple-negative breast cancer.
    Wu N; Zhang J; Zhao J; Mu K; Zhang J; Jin Z; Yu J; Liu J
    Oncol Lett; 2018 Oct; 16(4):4984-4996. PubMed ID: 30250564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer.
    Zhu X; Ying X; Liu Y; Wang Y; Chen L; Shao Z; Jin X; Jiang Y; Wang Z
    Cancer Biol Med; 2024 May; 21(9):784-98. PubMed ID: 38752685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update on Precision Medicine in Breast Cancer.
    Sachdev JC; Sandoval AC; Jahanzeb M
    Cancer Treat Res; 2019; 178():45-80. PubMed ID: 31209841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Opportunities and Challenges in the Development of Antibody-Drug Conjugate for Triple-Negative Breast Cancer: The Diverse Choices and Changing Needs.
    Tang Q; Li H; Zhao XT; Li ZY; Ma CX; Zhou SQ; Chen D
    World J Oncol; 2024 Aug; 15(4):527-542. PubMed ID: 38993251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Personalized treatment in metastatic triple-negative breast cancer: The outlook in 2020.
    Azim HA; Ghosn M; Oualla K; Kassem L
    Breast J; 2020 Jan; 26(1):69-80. PubMed ID: 31872557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.